Delcath Systems Death Spiral Financing And Luxurious Spending Will Result In A Speedily 90% Decline In Share Price
In the past month, Delcath has risen 1000%+ on promotional hype and no fundamental news.
Delcath is engaging in death spiral financing, the convertible note holders can buy shares at a 15% discount to the recent market price and then immediately sell in the open market.
Delcath’s outstanding share count went from 39 million on February 10, 2017, to 374.4 million on June 5th, 2017, and 439 million on July 5th.
Delcath is conducting clinical trials on its same technology that failed to be approved by the FDA in 2013.
Despite being a struggling company, Delcath’s gluttonous executives award themselves high salaries, fly first class, and are in a ritzy office located in midtown Manhattan.
Read the full article on Seeking Alpha here.
